colorectal cancer

FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
FDA grants priority review for Takeda and HUTCHMED’s fruquintinib NDA
Pharmaceutical Technology
Takeda
Hutchmed
FDA
fruquintinib
colorectal cancer
Flag link:
Guardant blood test detects 83% of colorectal cancer cases, but fewer in early stage
Guardant blood test detects 83% of colorectal cancer cases, but fewer in early stage
Medtech Dive
Guardant Health
diagnostics
Medtech
colorectal cancer
Shield
clinical trials
Flag link:
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
BioSpace
Merck
Keytruda
Eisai
Lenvima
melanoma
clinical trials
cancer
colorectal cancer
Flag link:
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Takeda focuses on ‘diverse’ pipeline prospects on heels of two acquisitions
Endpoints
Takeda
Nimbus Therapeutics
Hutchmed
colorectal cancer
psoriasis
fruquintinib
Flag link:
Guardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 35%
Guardant DNA blood test finds 83% of colorectal cancers in trial, shares fall 35%
Reuters
Guardant Health
DNA
diagnostics
colorectal cancer
EXACT Sciences
Flag link:
Pfizer and Erasca Target Pancreatic, Colorectal Cancer with "Synergistic" Pairing
Pfizer and Erasca Target Pancreatic, Colorectal Cancer with "Synergistic" Pairing
BioSpace
Erasca
Pfizer
ERAS-007
Ibrance
colorectal cancer
Flag link:
Scandion's shares fall after oncology biotech reports PhII fail
Scandion's shares fall after oncology biotech reports PhII fail
Endpoints
Scandion Oncology
clinical trials
colorectal cancer
SCO-101
Flag link:
Celyad gets the go-ahead to resume CAR-T trial for colorectal cancer as FDA lifts hold
Celyad gets the go-ahead to resume CAR-T trial for colorectal cancer as FDA lifts hold
Endpoints
Celyad
CAR-T
colorectal cancer
FDA
clinical trials
Flag link:
Merck to stop Phase 3 trial of Lynparza drug in colorectal cancer for futility
Merck to stop Phase 3 trial of Lynparza drug in colorectal cancer for futility
Seeking Alpha
Merck
clinical trials
Lynparza
colorectal cancer
Flag link:
Seagen's potential breast cancer blockbuster Tukysa shows promise in colorectal cancer
Seagen's potential breast cancer blockbuster Tukysa shows promise in colorectal cancer
Fierce Pharma
Seagen
Tukysa
breast cancer
colorectal cancer
clinical trials
Flag link:
Freenome aims to take on the big beasts
Freenome aims to take on the big beasts
EP Vantage
Freenome
liquid biopsies
colorectal cancer
diagnostics
Medtech
Guardant Health
Flag link:
Erasca, Eli Lilly partner for colorectal cancer therapy trial
Erasca, Eli Lilly partner for colorectal cancer therapy trial
Pharmaceutical Business Review
Erasca
Eli Lilly
clinical trials
ERAS-007
colorectal cancer
Flag link:
Deaths in Keytruda combo study spur Celyad to pause trial of off-the-shelf CAR-T cell therapy
Deaths in Keytruda combo study spur Celyad to pause trial of off-the-shelf CAR-T cell therapy
Fierce Biotech
Celyad Oncology
CAR-T
clinical trials
Keytruda
CYAD-101
colorectal cancer
Flag link:
Liquid biopsy developers take aim at colorectal cancer
Liquid biopsy developers take aim at colorectal cancer
EP Vantage
liquid biopsies
Medtech
diagnostics
colorectal cancer
EXACT Sciences
Guardant Health
Natera
Flag link:
Freenome gets $290M from Roche as it preps blood-based cancer test’s next steps
Freenome gets $290M from Roche as it preps blood-based cancer test’s next steps
MedCity News
Freenome
Roche
diagnostics
colorectal cancer
Flag link:
Servier Phase III colorectal cancer trial fails to meet primary endpoint
Servier Phase III colorectal cancer trial fails to meet primary endpoint
Pharmafile
Servier
colorectal cancer
clinical trials
Lonsurf
Flag link:
ESMO: Mirati pulls away from Amgen in colorectal cancer with rival KRAS drug
ESMO: Mirati pulls away from Amgen in colorectal cancer with rival KRAS drug
Fierce Biotech
ESMO
Mirati Therapeutics
Amgen
colorectal cancer
Flag link:
Cardiff reveals early data on challenger to Amgen's KRAS crown
Cardiff reveals early data on challenger to Amgen's KRAS crown
Fierce Biotech
Cardifff Oncology
Amgen
Onvansertib
colorectal cancer
Flag link:
ASCO 2021 – Guardant shoots for the moon
ASCO 2021 – Guardant shoots for the moon
EP Vantage
ASCO 2021
Guardant Health
liquid biopsy
colorectal cancer
Flag link:
Colorectal Cancer Screening Should Start At Age 45, Experts Recommend
Colorectal Cancer Screening Should Start At Age 45, Experts Recommend
NPR
diagnostics
colorectal cancer
Flag link:

Pages